Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in babies across the world. Irrespective of progress in the development of RSV vaccines, effective small molecule drugs are still not available on the market. Based on our previous data we designed and synthesized triazole-linked coumarin-monoterpene hybrids and showed that they are indeed effective in inhibiting the RSV replication. The most effective compounds are active against both RSV serotypes, A and B with IC50 in low micromolar or submicromolar range of concentrations. These are the most active coumarin derivatives found so far. Compound 45 commbining 3,7-dimethyloctane and cyclopentane-aanelated coumarin fragments has selectevity index 160 for serotipe A and 1147 for serotype B. According to the results of the time-of-addition experiments, the conjugates are active at the early stages of virus cycle. Based on biological evaluation and molecular modeling data, RSV F protein is a possible target.
You have access to this article
Please wait while we load your content… Something went wrong. Try again?